B Ferment, J Lambert, D Caillot, I Lafon, L Karlin, A Lazareth, C Touzeau, X Leleu, N Moya, S Harel, A Perrot, P Bories, L Vincent, S Lamure, M Mohty, F Malard, S Manier, I Yakoub-Agha, J-M Schiano De Colella, G Brisou, A Talbot, O Decaux, R Houot, S Le Gouill, N Bigot, T Facon, J Corre, P Moreau, B Arnulf
Idecabtagene vicleucel (ide-cel), a chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen (BCMA), received early access program (EAP) authorization in France in April 2021 for relapsed/refractory multiple myeloma (RRMM). We conducted a real-world registry-based multicentre observational study in 11 French hospitals to evaluate ide-cel outcomes. Data from 176 RRMM patients who underwent apheresis between June 2021 and November 2022 were collected from the French national DESCAR-T registry...
May 15, 2024: British Journal of Haematology